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The recent exponential increase in the use of engineered nanoparticles (eNPs) 
means both greater intentional and unintentional exposure of eNPs to microbes. 
Intentional use includes the use of eNPs as biocides; unintentional exposure results from 
the fact that eNPs are included in a variety of commercial products (paints, sunscreens, 
cosmetics.) Many of these eNPs include heavy metals or metal oxides such as titanium 
dioxide, silver, gold, zinc and zinc oxide. The fact that early studies of the impact of 
metallic nanoparticles achieved approximately 90% lethality to Ag, Cu eNPs, suggests 
that genetic variants are already circulating in bacteria that can be co-opted to provide 
heavy metal eNP resistance. This project has utilized laboratory experimental evolution 
to evolve eNP resistance in the bacterium Escherichia coli (K12 MG1655 strain.). This is 
currently being validated by demonstrating the greater fitness of evolved strains versus 
ancestral strains in the presence of different sized and coated silver nanoparticles (10nm, 
40nm, citrate-coated, PVP-coated) as well as phenotypic changes in the bacterial cell wall 
(as measured by Atomic Force Microscopy, AFM.).  Finally, the bacterial genomes of the 
evolved and ancestral strains were resequenced.  The genomic basis of this complex 
phenotype was determined. The practical application of such knowledge cannot be 
underestimated since nature is already evolving nanoparticle resistant bacteria. Thus 
knowledge of the nature of the physiological, morphological, and genomic mechanisms 
of resistance will be essential to deploy sustainable use of NPs as biocides, and to prevent 
unintentional environmental damage.
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CHAPTER I 
 
INTRODUCTION 
 
 
Emerging outbreaks of infectious disease and widespread resistance to 
conventional antimicrobial drugs are significant global public health problems, and there 
has been an increasingly aggressive search for new antimicrobial agents (Jones et al., 
2008; M. Rai, Yadav, & Gade, 2009). Antibiotic resistant organisms that are  causing 
dangerously untreatable clinical infections is a growing global and national problem for 
human and agricultural health (Chait, Vetsigian, & Kishony, 2012). Furthermore, 
resistance can be horizontally transmitted to other hosts accelerating the epidemic spread 
of antibiotic-resistant infections (Bonhoeffer, Lipsitch, & Levin, 1997).  Thus drug 
resistant organisms are rapidly spreading inside hospitals, healthcare settings, food and 
water sources as well as in the community. When treatment failure happens, second or 
third choice drugs may be required that might be less effective, more toxic, and more 
expensive (CDC, 2012; Nelson DuránI, 2010).  Maintaining the efficacy of existing 
antibiotics is reasonable strategy in the current conditions.  This is because the  rate of 
new drug discovery is slow and the fact that microbes are constantly evolving resistance 
to those that are developed (Chait et al., 2012).   
For the reasons above, metallic and metallic oxide nanoparticles are being 
proposed as the new “miracle” antibiotics (Rai et al. 2012.)  Silver nanoparticles have 
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been extensively employed as antimicrobials (Rai, Yadav, and Gade 2009).  Silver have 
been used for its medical and antimicrobial effects from the ancient Romans to the water 
treatment systems in to the Apollo, MIR and the Space shuttle programs.(Prabhu & 
Poulose, 2012; R. S. Rai & Subramanian, 2009; Silver & Phung, 2005; Xiu, Zhang, 
Puppala, Colvin, & Alvarez, 2012). Past examples of the antimicrobial use of silver 
include its use for water treatment in 1000 BCE, the use of silver nitrate to treat venereal 
disease in 1700 CE, and the use of silver nitrate to treat fresh burns from at least the 18th 
century forward (Castellano et al., 2007; Prabhu & Poulose, 2012; R. S. Rai & 
Subramanian, 2009; Xiu et al., 2012).  In addition, various types of silver compounds 
with nitrate, sulfadiazine,  zeolite,  powder,  oxide,  chloride and silver cadmium powder  
have been used as antimicrobials from ancient times (M. K. Rai, Deshmukh, Ingle, & 
Gade, 2012). In modern times, silver has been successfully used as an antimicrobial. For 
example, Spadaro et al. (1974) utilized silver electrodes with weak direct current to 
inhibit the growth on agar plates of Staphylococcus aureus, Escherichia coli, Proteus 
vulgaris, and Pseudomonas aeruginosa.  Also a recent study showed silver effective 
against 16 major species of bacteria (Prabhu & Poulose, 2012). 
1.1 Nanoparticle Characteristics and their Impact on Microbes 
Nanoparticles have been proposed to be effectiveness antimicrobials due to their 
high surface-to-volume ratio and their unique chemical and physical properties which are 
often best realized through the use of metallic compounds (Kim et al., 2007; Jose Ruben 
Morones et al., 2005; M. Rai et al., 2009). Sondi and Salopek-Sondi (2004) is one of the 
earliest studies that examined specifically the impact of silver nanoparticles (AgNP) on 
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bacterial growth (Sondi & Salopek-Sondi, 2004). Their study with Escherichia coli and 
12 nm diameter nanoparticles suggested that if the primary mechanism of biocidal action 
is Ag+ ions, then AgNPs would be more effective than bulk silver. In all treatments (10, 
50, and 100 µg/cm3), there was a significant delay in bacterial growth and lower 
population size achieved at the end of 9 hours relative to the control (0 µg/cm3).  Sondi 
and Salopek-Sondi (2004) argued that this was because the concentration of the AgNPs 
decreased with time in the culture and interaction of the AgNPs with the intracellular 
substances of the destroyed cells. Their scanning electron microscope (SEM) images 
showed that AgNPs coagulated with dead bacterial cells, thus reducing the concentration 
of them and Ag+ ions in the liquid medium. Subsequent studies have confirmed these 
general findings (Baker, Pradhan, Pakstis, Pochan, & Shah, 2005; Jose Ruben Morones et 
al., 2005; Pal, Tak, & Song, 2007; Panáček et al., 2006; Shahverdi, Fakhimi, Shahverdi, 
& Minaian, 2007).  These impacts of AgNPs have also been found for natural microbial 
communities (Burchardt et al., 2012; Merrifield et al., 2013).   
Nanoparticle morphology (size, shape) is an important determinant of toxicity to 
bacteria with smaller NPs being most effective than larger NPs (Baker et al., 2005; 
Panáček et al., 2006).  Morones et al. (2005) studied NPs in the range of 1 – 100 nm 
diameters and found that toxicity was enhanced based on a lower size range (1 – 10 nm), 
and observed a range of varying NP shapes through transmission electron microscopy 
(TEM; (Jose Ruben Morones et al., 2005). Pal et al. (2007) found that truncated 
triangular AgNPs displayed the greatest effect on E. coli, compared to spherical and rod-
shaped NPs (Pal et al., 2007).   
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Nanoparticles are generally produced by spark discharging, electrochemical 
reduction, solution irradiation and cryochemical synthesis, and biological processes.  The 
method by which the particle is produced  has important impacts on its physicochemical 
properties, such as pH-dependent partitioning and biological  activity, as compared to 
bulk material (Birla et al., 2009; M. K. Rai et al., 2012; Shahverdi et al., 2007; Sondi & 
Salopek-Sondi, 2004; Wu & Hsu, 2008).  Chemical methods require some sort of 
compound coating the AgNPs to prevent further aggregation. For example, Sondi, Goia, 
and Metijevic` (2003) utilized Daxad 19, a sodium salt of high molecular weight 
naphthalene sulfonate formaldehyde to prevent NP aggregation (Sondi & Salopek-Sondi, 
2004). Others have used citrate (C6H5Na3O7), thiosalicyclic acid (C6H4 (SH) CO2H, 
IUPAC name, 2-mercaptobenzoic acid), or polyvinylpyrrolidone (PVP, IUPAC name 1-
ethenylpyrrolidin-z-one) as coating agents for AgNP production. The fact that these 
coatings have different solubility’s would result in them impacting solution pH 
differently.  This in turn may result in the NPs adhering to biological cell walls 
differently.  This suggests that coating type may play a crucial role in how AgNPs kill 
bacteria.  El Badaway et al. (2011) showed that toxicity of AgNPs was dependent on 
more negatively charged particle coating. In a study performed on Bacillus spp., they 
found toxicity increased along the following series of coatings: uncoated (H2—AgNPs), 
citrate coated (Citrate-AgNPs), polyvinylpyrrolidone coated (PVP-AgNPs), and branched 
polyethyl-eneimine coated (BPEI-AgNPs) (El Badawy et al., 2011).      
Schacht  et al, 2013, briefly describe the mechanism of nanosphere Ag(0) silver 
nanoparticles in three steps 1) attachment of Ag(0) nanoparticles to the cell surface and 
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altering the physical,  chemical,  and functional properties of the cell membranes 2) 
adding more damage to bacterial cells by permeating the cell, DNA, proteins and other 
phosphorus- and sulfur-containing cell constituents interaction 3) silver ions release and  
generating an amplified size and dose dependent biocidal effect (Schacht et al., 2013).  
The antimicrobial activity of silver has been established to be due to Ag+ ions in a 
number of studies going back at least to the 1970’s(Mijnendonckx, Leys, Mahillon, 
Silver, & Van Houdt, 2013). Cell lysis or inhibition of cell transduction, interaction with 
thiol (-SH) groups of membrane-bound enzymes or proteins and  effects on respiratory 
chain of bacteria has been acknowledged as sources of the antimicrobial effects of silver 
nanoparticles.  Also AgNPs have lower relative therapeutic doses compare to other 
antimicrobials (Olesja Bondarenko, 2013; Prabhu & Poulose, 2012; Xiu et al., 2012) and 
it has been claimed that due to the fact AgNPs impact so many bacterial systems that 
there is a  lower chance of developing antimicrobial resistance to them (Jain et al., 2009; 
Madhavan, Rosemary, Nandkumar, Krishnan, & Krishnan, 2011).    
While the exact mechanisms of silver nanoparticle toxicity to bacteria are not 
fully known, there is a growing consensus concerning the candidate actions. For example, 
some studies have shown that the toxicity of AgNps can be influenced by adding 
functional groups to the particle ( e.g. sulfidation reduces toxicity, Levard et al. 2013.)   
Bondarenko et al. 2013 found that cell NP contact increases the dissolution rate of Ag+ 
ions and hence their toxicity on six bacterial species (E. coli, Pseudomonas flourescens, 
P. putida, P. aeruginosa, Bacillus subtilis, and Staphylococcus aureus).   First, the action 
of silver nanoparticles occurs both by the release of silver ion (Ag+) as well as from 
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potential disruption or damage to the cell wall and membrane caused by the particles 
themselves(Mijnendonckx et al., 2013; M. Rai et al., 2009; M. K. Rai et al., 2012). Silver 
interacts with the thiol group compounds found in respiratory enzymes of bacterial cells. 
It also binds to the bacterial cell wall and cell membrane inhibiting the respiration process 
(Klasen, 2000; M. Rai et al., 2009).   
Silver is known to act on E. coli by inhibiting the uptake of phosphorous and 
releasing phosphate, mannitol, succinate, proline, and glutamine from the cells (M. K. 
Rai et al., 2012; Yamanaka, Hara, & Kudo, 2005). The penetration of silver ions inside 
the cell is thought to impact the ability of DNA to replicate by causing it to condense. 
Due to the large surface area to volume ratio, smaller AgNPs should be able to more 
effectively release Ag+ ions into the cell and, following attachment to the cell membrane, 
may also penetrate into the cell (Mijnendonckx et al., 2013; Jose Ruben Morones et al., 
2005; Pal et al., 2007; M. K. Rai et al., 2012). Once inside, Ag+ ions may be lethal as 
they disrupt metabolism, cell signaling, DNA replication, transcription, translation, and 
cell division, either directly or through the generation of reactive oxygen species 
(ROS)(Mijnendonckx et al., 2013; M. K. Rai et al., 2012).  
 Silver resistance bacteria were repeatedly found in burn wounds, clinical and 
natural environments, teeth. In all E. coli strains, cus CFBARS determinants in 
chromosomally located area partly caused by single point mutation that are functioning to 
develop, Ag+ binding proteins, ATPase efflux pump, spans the entire cell membrane and 
pumping Ag+ from the periplasm to the exterior of the cell. Lack of this determinant can 
take  about 100 times more sensitive strain(Mijnendonckx et al., 2013).  In summary, the 
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toxicity of AgNPs upon bacteria appears dependent on particle shape, size, and 
concentration (> 75 ug/ml usually ceases growth(M. K. Rai et al., 2012). The toxicity of 
AgNPs is determined by the dissolution rate.  In addition the toxicity of AgNPs differed 
widely between six species of bacteria tested (gram positive and gram negative; 
(Martinez & Baquero, 2000; Olesja Bondarenko, 2013).  
Moreover, it has been shown that the morphological properties of AgNPs  have 
indirect effects on the release of  Ag+ ions.  Thus AgNP antimicrobial activity is a 
combination of oxygen availability, particle size, shape, and/or type of coating, 
aggregated state, stability of the preparation, dosage and speciation of the released silver 
(Burchardt et al., 2012; Wilkinson, White, & Chipman, 2011; Xiu et al., 2012). This 
study tests the generality of these results by specifically comparing two different 
commonly used coatings (citrate, PVP) and examine toxicity for 10 nm and 40-nm 
AgNPs in the model gram-negative bacterium Escherichia coli.   
1.2 Nanoparticles and the Environment  
 Increasing amounts of metallic/metallic oxide nanoparticles are being used in 
consumer products.  For example, nano-TiO2 is produced on a large scale for applications 
in paints, cosmetics, sunscreens, photocatalysts and solar cells, as well as water 
purification devices (Mu and Sprando 2010; Planchon et al. 2013.) In 2008 the 
concentration of nano-TiO2 predicted for American soil, sludge, surface water, sewage 
treatment plant (STP) effluent, STP sludge, and sediment were 0.53 mg/kg/year, 42.00 
mg/kg/year, 0.002 mg/L/year; 1.75 mg/L/year; 137 mg/kg/year, and 53 mg/kg/year, 
respectively (Gottschalk et al. 2009.)   Similarly values for nano-Ag were calculated at 
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6.6 mg/kg/year, 526 mg/kg/year, 0.088 mg/L/year, 16.40 mg/L/year, 1.29 mg/kg/year, 
and 153 mg/kg/year, respectively.  
In addition there are increasing concentrations of metals entering natural 
environments e.g. wastewater effluents (e.g. industry, hospitals, dental offices, etc.) and 
water flow from metal mines over the last decade. Therefore there is great potential for 
environmental and agricultural damage caused by silver nanoparticles due to rapidly 
increasing quantities and varieties of this antimicrobial (Bradford, Handy, Readman, 
Atfield, & Muhling, 2009; Dobias & Bernier-Latmani, 2013; Jain et al., 2009; Martinez 
& Baquero, 2000; Reinsch et al., 2012; Schwab, 2012; Z. Zhang, Kong, Vardhanabhuti, 
Mustapha, & Lin, 2012) and widespread and uncontrolled use of silver may cause more 
bacterial resistance (Gupta & Silver, 1998). Already considerable modification in the 
structure and function of microbial communities has been caused by introduction of  
various forms of heavy metals such as Zn, Cu, Cr, Mn and Hg and Ag that some of them 
even have nutritional values (Bednorz et al., 2013; Hacioglu & Tosunoglu, 2014; Silva et 
al., 2012). In addition increased metal concentration may cause greater  dissemination of 
mobile genetic elements and novel phenotypes among bacterial populations 
(Mijnendonckx et al., 2013).  
The idea that increased use of silver as a biocide will generate novel phenotypes is 
evidenced from silver resistant bacterial strains isolated from patients in the Veterans 
Administration Hospital in Syracuse, NY.  Strains living in hospitals have been exposed 
to a number of biocides and in general should be “tougher” than stains living in the 
general environment.  Indeed, silver-resistant bacteria have been repeatedly found in burn 
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wards, clinical and natural environments, and on human teeth (Toprak et al., 2012). It has 
been shown that improper waste water treatment and fail to remove bio- pollutants are 
causing the contamination of surrounding environment and created a favorite habitat for 
emergence of new pathogens,  containing new resistance and virulence genes  and may 
facilitate their persistence, co-selection, and dissemination (Gomez-Sanz et al., 2013; 
Hacioglu & Tosunoglu, 2014; Varela & Manaia, 2013).  
Considerable modification in the structure and function of microbial communities 
has been caused by introduction of  various forms of heavy metals such as Zn, Cu, Cr, 
Mn and Hg and Ag that some of them even have nutritional values (Bednorz et al., 2013; 
Hacioglu & Tosunoglu, 2014; Silva et al., 2012).  However, the presence of have metals 
such as chrome, nickel and mercury might have counter-selective effects against 
antimicrobial resistant strains against E. coli strains (Holzel et al., 2012).  
1.3 Potential For NP Resistance 
The chief mechanism of evolution is natural selection.  For natural selection to 
operate a population must be variable, the trait in question must be heritable, and there 
must be a struggle for existence.  We know that the mutation rate per bacterial nucleotide 
ranges between 10-7 to 10-10 (Ford et al. 2011; Ycart and Veziris 2014).  This translates to 
a mutation rate per genome at about 10-1 to 10-3.  Indeed, the mutation rate per genome 
for E. coli K12 MG1655 (the bacterium used in these experiments) is around 0.87 – 1.51 
x 10-3 per genome (Lee et al. 2012.)  This means that since bacteria maintain large 
populations there are an ample number of mutations to allow bacterial evolution to 
proceed quickly.   
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Since mutations are changes in the genetic code they are passed on to the mutant’s 
daughter cells.  While most mutations are deleterious; a significant fraction are neutral, 
and an even smaller fraction that are beneficial.  Beneficial mutations may rapidly sweep 
to high frequency when they confer an advantage against environmental toxins such as 
antibiotics or heavy metals (Levin, Perrot, Walker 1999; Miller, O’Neill, Chopra 2002; 
Burke 2012).  Given what we already know about bacterial evolution, it seems 
contradictory that researchers developing new applications of metallic/metallic oxides for 
bacterial control have not considered if and how quickly resistance to these nanomaterials 
will evolve (Graves 2014.). 
We already have the experience of the rapid bacterial evolution of resistance to 
traditional antibiotics (Baquero and Blazquez 1997; Levin, Perrot, and Walker (2000.)  
Over forty years ago, Streptococcus pneumoniae was considered widely susceptible to 
penicillin and other β-lactam antibiotics.  Shortly afterwards, resistance to these 
antibiotics was reported all over the world, such that by 1997 resistance rates exceeded 
30—70% of isolates derived from patients (Baquero and Blazquez 1997).  Thus, 
understanding the mechanisms of evolution we should expect that despite the fact that 
metallic/metallic oxides NPs impact a great number of bacterial systems that the 
evolution of resistance to them is already occurring in nature. 
Resistant genotypes seem to have lower growth rates than their sensitive 
counterparts in the absence of antimicrobials(Lenski, 1998). The mechanism of most 
bacterial heavy metal resistance results from energy-dependent ion efflux from the cell by 
membrane proteins that function either as ATPases or as chemiosmosis cation/proton 
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antiporters (Silver, 2003).  The fact that these resistance mechanisms are already 
circulating in nature suggests that even naïve bacteria could acquire resistance in due to 
horizontal gene transfer.  This could occur from food ingestion or inside gastrointestinal 
system (Durso, Miller, & Wienhold, 2012) resulting from sequential accumulation of 
multiple beneficial mutations or a single amino acid exchange (Tyerman, Ponciano, 
Joyce, Forney, & Harmon, 2013). 
Single amino acid substitution has more advantage and could create rapid fixation 
within hundreds of generations in the presence of antibiotics (Tyerman et al., 2013). 
Spontaneous mutation is an important source of variation driving the evolution of 
resistance, however, developing strong resistance requires multiple mutations for most 
antimicrobials (Toprak et al., 2012). It is also not clear how the evolution of biofilm 
formation contributes to the development of antimicrobial resistance (Tyerman et al., 
2013). Moreover, our lack of understanding of the morphological and genomic changes 
of bacteria via natural selection at sub-lethal levels of silver nanoparticles will result in 
unforeseen problems such as the rapid emergence of silver nanoparticle resistance 
(Furuya & Lowy, 2006).  
In addition to de novo evolution of silver nanoparticle resistance we can expect 
that existing silver resistance genetic elements will be co-opted by bacteria in nature to 
survive elevated silver concentrations.  For example, the R- Plasmid is known to be one 
of the most common transmissible instruments for resistance through conjugation and 
transformation (Shoeb et al., 2012). In addition, a silver resistance plasmid of the IncHI 
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incompatibility group confers resistance to silver, mercury, tellurium, as well as several 
antibiotics (Gupta et al. 1999.)   
This study avoids the complication of plasmid borne resistance by using E. coli 
K12 MG1655 a strain that has no plasmids.  Table 1 show a list of existing antimicrobial 
resistance genes that are carried by E. coli (Furuya & Lowy, 2006).  However, we do not 
have a-priori knowledge of how genomic variation will combine to produce resistance to 
silver nanoparticles in this particular strain of the bacterium.  Whole-genome studies are 
beginning to demonstrate that the naïve “candidate” gene approach is simply inadequate 
to predict genomic evolution under different environments (e.g. Graves et al. in prep). In 
this study, Illumina resequencing via the MiSeq platform was used to determine which 
genomics variants were associated with evolved silver nanoparticle resistance. This 
allows comparsions of the resistance elements that evolved in this bacterial strain under 
our culture conditions, with previously scored resistance elements (e.g. Silver 2003).  
1.4 Molecular Genetics of Silver Resistance 
Current genomic evidence suggests that the sil Ag (I) resistance system may have 
evolved from an earlier existent pco copper resistance system.  Salmonella spp. and E. 
coli genomes contain six genes (silA through sil S) that produce products that are closely 
homologous to a gene cluster on the Escherichia coli genome renamed as agr A, agr B, 
agr C, agr R, agr S in E. Coli K-12 and E. coli O157:H7.  SilS (a histidine- containing 
membrane ATP kinase ‘sensor’) and silR (a cytoplasmic DNA-binding activator 
‘responder’ that contains an aspartate residue that is trans-phosphorylated from SilS) are 
two genes that are transcriptionally responsible for silver resistance systems. The plasmid 
13 
 
borne silver resistance gene silAB ORF96silCRS is closely homologous to chromosomal 
gene regions in E. coli K-12 and O157:H7.  SilP belongs in the family of heavy metal 
resistance efflux ATP-ases. It is reported that a deletion of DNA in the middle of silP 
results in reduced silver resistance. It has also been shown that silP eflux ATPase pump 
for cations such as cadmium, zinc  or copper provides cation binding for transport and its 
modulation which is not significant in Ag efflux pumping system and detail functional 
studies has not been developed (Silver, 2003). 
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CHAPTER II 
 
EXPERIMENTAL EVOLUTION OF SILVER NANOPARTICLE RESISTANCE 
 
 
Experimental evolution is defined as research in which populations are studied 
across multiple generations under defined and reproducible conditions either in the 
laboratory or in nature (Garland and Rose 2009.)  In laboratory natural selection 
experiments some aspect of the environment of laboratory maintained organisms is 
altered; e.g. culture, medium, food, temperature, humidity, etc.)  The methodology has 
been long used in evolutionary biology going back to the work of Th. Dozhansky in the 
1940’s.  It’s successes in elucidating the nature of adaptation to a wide variety of 
environmental features are many; including the iconic long term evolution experiments of 
the Lenski laboratory in E. coli (Lenski et al. 1991; Lenski and Travisano 1994).  Recent 
successes of this method particularly relevant to bacterial adaptation include Herring et 
al. 2006 (demonstrating bacterial adaptation on the laboratory time scale); and Tenaillon 
et al. 2012 (utilized > 100 replicates lines to demonstrate adaptive convergence in E. 
coli.).  
This study utilized the experimental evolution methodology of these previous E. 
coli experiments to examine the evolvability of silver nanoparticle resistance.  It was 
designed to determine how quickly silver nanoparticle resistance could evolve in a 
previously non-resistant E. coli K12, MG1655, a strain that had no previously known 
silver resistance genetic (sil) elements.  The control populations were maintained in 
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standard medium without the addition of AgNPs.  Both control and treatment groupswere 
replicated five-fold.  After transfer to found the next generation, the remainder of each 
replicate was frozen in -80o for future analysis.  The treatment populations were exposed 
to increasing concentrations of spherical 10nm citrate-coated AgNPs.  The AgNPs were 
citrate-coated due to the need to prevent agglomeration of the particles.  Citrate was 
chosen for this experiment due to the inability of citrate to be metabolized by E. coli 
(Blount et al. 2012).  Our laboratory has studied the impact of two commonly used silver 
nanoparticle coating types (citrate and polyvinylpyrolidone, PVP) on bacteria (Tajkarimi 
et al. 2014.)  Generally, we found that citrate-coated were more effective against E. coli 
K12 MG1655 than PVP-coated.   
The selection protocol consisted of culturing E. coli  K-12 MG1655 using Davis 
Minimal Broth (DMB, DifcoTMSparks, MD ) with dextrose 10% as a sole carbon source, 
enriched with thiamine hydrochloride 0.1% (Thiamine Hydrochloride, Fisher scientific, 
Fair Lawn, NJ) in 10 ml of total culture volume maintained in 50 ml Erlenmeyer flasks. 
The flasks were placed in a shaking incubator at 37o C for 24 hours. Cultures were 
propagated by daily transfers of 0.1 ml of each culture into 9.9 ml of DMB.  This method 
is called the serial transfer in liquid medium protocol (Rosenzweig and Sherlock 2009.)  
There are other methods that can be used for laboratory experiments in bacteria, 
including the serial transfer in solid medium, and the continuous medium (chemostat) 
method.  These methods differ in a number of attributes.  For example, serial transfer 
experiments always involve a series of reduction in population size compared to  
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chemostat experiments where this does not occur.  Thus it is likely that some of the 
results reported in this study are related to the type of experimental protocol used.  
Therefore this experiment was not designed to be all inclusive of every potential 
environmental circumstance under which bacteria may be exposed to AgNPs but rather is 
designed to test the hypothesis that evolution to AgNPs is possible under some 
environmental conditions. 
The toxicity of metallic/metallic oxide NPs upon bacteria appears dependent on 
particle composition, shape, size, coating, and concentration (AgNPs concentrations of  > 
75 mg/ml usually ceases growth; Rai et al. 2012; Tajkarimi et al. 2014).  It was 
determined that minimal growth of E. coli K12 MG1655 was observed at 50 g/l so this 
was chosen as the initial concentration for the evolution of resistance studies.  As 
bacterial cultures showed evidence of growth (observed as turbid cultures by inspection) 
the concentration of AgNPs in the base cultures for the treatment group was increased 
(per schedule shown in Table 2.)  The optical density measurements showed that under 
these conditions that the cultures grew from about 106 to about 108 bacteria per ml at the 
end of 24 hours, having undergone about 6.5 generations. 
 The fact that increasing concentrations of AgNPs were used made this a 
directional selection experiment.  In directional selection the population mean of a trait is 
shifted to higher or lower values by exposing each succeeding generation to either a 
greater or lesser amount of specific environmental variable. To determine the 
concentration most favorable to begin the selection experiment the bacteria were  
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systematically exposed to the concentrations of 1 mg/l, 10 mg/l, 25 mg/l, 50 mg/l and 100 
mg/l.  These concentrations effectively wiped out bacterial growth compared to the 
control treatment (0 mg/l).  Therefore the treatment concentrations were lowered to 50 
µg/l, 100 µg/l, 250 µg/l, 500 µg/l, 750 µg/l and 1000 µg/l.  The 50 µg/l concentration was 
chosen as the initial concentration for the resistance studies.   
After 50 generations of bacterial growth at this concentration, the treatment 
populations were exposed to 100 µg/l.  This concentration was maintained for another 90 
generations.  After this the selection concentration was increased to 125 µ/l. This 
concentration was carried out for 125 generations.  After 45 generations of exposure at 
this concentration it was observed that several of treatment replicates were losing 
viability.  To rescue these populations, all replicates were combined.  Five new replicates 
were created by sampling from the mixed pool.  These were propagated without selection 
for AgNP resistance for  for an additional 40 generation before the  new  replicates were 
again exposed to another 80 generations of 125 µg/L AgNps.  
 After 45 generations of growth in the 125 µg/L, these replicates were combined 
to form a “cocktail” to assay their silver resistance relative to the controls (that were also 
cocktailed.)  The cocktail protocol was used due to a shortage of labor and materials. 
Table 2 shows the schedule of exposure concentrations used in the selection protocol.  
After 140 generations the exposure for the selected cultures had increased by 250%.
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CHAPTER III 
 
GENOTYPING SILVER NANOPARTICLE RESISTANCE; 
ANTIMICROBIAL ASSAYS 
 
 
3.1 What Are Antimicrobial Assays? 
 
 Antimicrobial assays evaluate the effectiveness of antimicrobials or certain 
procedures against bacteria , mold and yeasts (Bharitkar et al., 2014; Hajmeer et al., 
2011; Salam A. Ibrahim, 2011; M. Tajkarimi & Ibrahim, 2011; M. Tajkarimi et al., 2008; 
M. M. Tajkarimi, Ibrahim, & Cliver, 2010; M. X. Zhang et al., 2014). Antimicrobial 
quantifications in most experiments are based on two protocols, MIC (Minimum 
Inhibitory concentration) and MBC (minimum bactericidal concentration), which is 
presumably greater than the MIC. 
MIC is defined in different terms; some of them are ‘‘lowest concentration 
resulting in maintenance or reduction of inoculum’s viability,” ‘‘lowest concentration 
required for complete inhibition of test organism up to 48 hours incubation,” ‘‘lowest 
concentration inhibiting visible growth of test organism,” or ‘‘lowest concentration 
resulting in a significant decrease in inoculum’s viability (>90%).(M. M. Tajkarimi et al., 
2010)”  or”  the lowest concentration of a particular substance needed to inhibit the 
growth of a certain population of bacteria”(Kedziora et al., 2013).  MBC is defined as 
‘‘concentration where 99.9% or more of the initial inoculum is killed” or ‘‘lowest 
concentration at which no growth is observed after sub-culturing into fresh broth. 
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(M. M. Tajkarimi et al., 2010). The MIC method is cited by most researchers, but some 
quote MBC as a measure of antibacterial performance.  Several antimicrobial assays are 
currently being used; here is a brief description of some of them: 
Dilution plating and colony forming units enumeration is one of the methods that 
could be used to investigate the efficiency of the antimicrobials (Singh, Shiha, & Kumar, 
2014). Disc-diffusion method is an approved method by the Food and Drug 
Administration (FDA) as a standard for the National Committee for Clinical Laboratory 
Standards. This method is usually used for preliminary studies.  In this method, a paper 
disc soaked with the antimicrobial is placed on the inoculated surface of an agar plate and 
the zone of microbial inhibition is measured.  There are other antimicrobial test methods 
such as drop-agar-diffusion method, broth microdilution method and direct-contact 
technique in agar (M. M. Tajkarimi et al., 2010).  
3.2 Materials and Methods for Antimicrobial Assays 
3.2.1 Bacterial Culture 
We cultured E. coli  K-12 MG1655 using Davis Minimal Broth (DMB, 
DifcoTMSparks, MD ) with Dextrose 10% (Dextrose, Fisher Scientific, Fair Lawn, NJ) as 
a sole carbon source, enriched with thyamine hydrochloride 0.1% (Thyamin 
Hydrochloride, Fisher scientific, Fair Lawn, NJ) in 10 ml of total culture volume 
maintained in 50 ml Erlenmeyer flasks. The flasks were placed in a shaking incubator 
with temperature maintained at 37o C for 24 hours. Cultures were propagated by daily 
transfers of 0.1 ml of each culture into 9.9 ml of DMB. 
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3.2.2 Measuring Bacterial Growth 
Bacterial growth in BHI broth samples was assessed by measuring turbidity at 
620 nm for hours 0, 3, 6, 12 and 24, using a 98-well plate Synergic Mx 
spectrophotometer (Biotek, VA USA) using clear polyester 98-well plates. 
3.2.3 Bacterial Enumeration 
Bacterial populations were determined by spread plating on DM agar. In this 
procedure, samples were withdrawn from inoculated samples at 0 and 24 h and were 
serially diluted in 0.1% peptone water. Appropriate dilutions were surface plated (100 µl) 
onto duplicate DMA plates.  
3.2.4 Antimicrobials Susceptibility Tests 
            The antibiotic susceptibility test was performed using the standard disk diffusion 
method (Bauer, Kirby, Sherris, & Turck, 1966).  
3.2.5 Disk Diffusion Assay 
A 0.5 McFarland standard is equivalent to a bacterial suspension containing 
between 1 x 108 and 2 x 108 CFU/ml of E. coli cells. The total number of bacteria were 
adjusted to the 0.5 McFarland standard and spread on the agar DMA plate. Then disks 
including 30 µg chloramphenicol as a positive control were inserted into the agar plate 
and the results were measured after 24 hours of incubation of the plated cells at 37 C. 
3.2.6 Broth Micro Dilution Method 
Preparing bacteria: 
Overnight culture prepared and adjusted by McFarland standard at 0.5 McFarland 
turbidity. This results in a suspension containing approximately between 1 to 2 x 108 
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CFU/ml. The absorbance at 625 nm should be 0.08 to 0.13 for the 0.5 McFarland 
standards. Within 15 minutes of preparation, the inoculum suspension is adjusted in 
water, saline, or broth.  After inoculation the bacteria are diluted 10 times and 5 µl of the 
inoculum is added to each well.  In this case, we have about 5 x 104 CFU/well. Next  50 
µl of the MH broth is added to each well.  We used 1mg/ml= 1g/L of the AgNPs and 
made systematic dilution series to find the proper antimicrobial concentration. The 12 
dilution series were prepared as follows: 
1. SOLUTION 1: 120 µl of 10nm citrate coated AgNPs (1mg/ml) were taken and 
added to 100 mg/l 1080 µl of DI water.  
2. 500 µl of SOLUTION 1 is added to two centrifuge tubes labeled “ C1 ” and 
diluted with 500 µl of DI water 
3. 350µl of SOLUTION 1 is added to two centrifuge tubes labeled “ C2 ” and 
diluted with 650 µl of DI water 
4. 200 µl of SOLUTION 1 is added to eight centrifuge tubes labeled 20 mg/l “A” 
and diluted with 800 µl DI water  
5. 250 µl of  “A” is added to four centrifuge tubes labeled 5mg/l “ D” and diluted 
with 750 µl DI water 
6. 500 µl of “D ” added to three centrifuge tubes labeled “G” and diluted with 500 µl 
DI water 
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3.2.7 Plate Process Column 
1. After adjusting the culture with 0.5 McFarland standard it was diluted 10 
times (50 µl of the adjusted culture was added and diluted with 45 µl of 
Broth). Then 95 µl of MH Broth x 5 µl of the stock culture was added.) 
2. 50 µl of SOLUTION 1 and 45 µl of broth x 5 µl culture 50 mg/l 
3. 50 µl of “ C1 ” and 45 µl of broth x 5 µl  culture 25 mg/l 
4. 50 µl of “ C2 ” and 45 µl of broth x 5 µl culture 17.5 mg/l 
5. 50 µl of “ A ” and 45 µl of broth x 5 µl culture 10 mg/l 
6. 37.5 µl of  “ A ” and 57.5 µl of broth x 5 µl culture 7.5 mg/l 
7. 25 µl of “ A ” and 70 µl broth x 5 µl culture 5 mg/l 
8. 12.5 µl of “ A ” and 32.5 µl broth x 5 µl culture 2.5 mg/l 
9. 25 µl of “ D ” and 70 µl broth x 5 µl culture 1.25 mg/l 
10. 12.5 µl of “ D ” and 82.5 µl broth x 5 µl culture 625 µg/l 
11. 6.25 µl of “ D ” and 88.75 µl broth x 5 µl culture 312 µg/l 
12. 25 µl of “G” and 70 µl broth x 5 µl culture 156 µg/l 
 
3.3. Visual Characterization Techniques  
 
3.3.1 Electron Microscopy 
Scanning Electron Microscopy bacterial preparation 
 SEM preparation was conducted using aldehyde fixative for a minimum of one 
hour using Karnovsky’s glutaraldehyde, followed by 2% paraformaldehye/2% 
glutaraldehyde in 0.1M phosphate buffer for another hour, post-fixation with osmium 
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tetroxide and cacodylate phosphate buffer for one hour and washing with deionized 
water, followed by applying a series of graded acetonitrile using concentrations of 50, 70, 
90, 95, and 100%. Images were generated using Zeiss Auriga BUFIBFE SEM. 
3.3.2 Atomic Force Microscopy 
In force spectroscopy, the AFM cantilever is moved in the z-direction and its 
position is recorded. The force acting on the cantilever movement is calculated as a 
spring constant and recorded by a force distant curve with pN (1012 N) sensitivity 
(Dufrene & Pelling, 2013). AFM has been used successfully in the following 
applications: submolecular-resolution imaging, in situ observation, and nanomechanics 
measurement(Zhong & He, 2012).  
Lifshitz-Van der Waals adhesion forces  play an important role in the adhesion of 
bacteria to various surfaces (Chen, Harapanahalli, Busscher, Norde, & van der Mei, 
2014). Antimicrobial compounds, could disrupt the peptidoglycan layer and inhibit 
protein or DNA synthesis. These physiological changes to the bacterial physical 
properties, such as their elasticity and viscosity and measurement of these properties 
could provide important insights into the mechanism of action of antibiotic agents 
(Vadillo-Rodriguez, Beveridge, & Dutcher, 2008). Comprehensive understanding of 
interaction between bacterial cell surface and the related change in contact area is 
required to consider the viscoelasticity of the bacterial cell surface.  The qualitative 
differentiation of bacterial viscoelastic properties has yet to be applied to studying 
bacterial biofilms (Nunez et al., 2005; Volle, Ferguson, Aidala, Spain, & Nunez, 2008).      
Understanding bacterial viscoelastic properties is becoming more important because it is 
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now believed that bacterial colonization and biofilm formation are intimately related to 
substrate adhesion forces.  The ability of bacteria to persist in biofilms is plays a  critical 
role in infectious disease (Childers, Van Laar, You, Clegg, & Leung, 2013; Haraguchi, 
Miura, Fujise, Hamachi, & Nishimura, 2014). Understanding the adherence mechanism 
to solid surfaces is an important step to understand the communal lifecycles of bacteria 
(Rogers, van der Walle, & Waigh, 2008). Current elastic deformation experimental 
models are unable to distinguish between the resistant and non-resistant strains bacterial 
cell surface and substrate enveloped by systematic interventions. Therefore, we utilized 
AFM methods to estimate deformation and elastic deformation of adhering bacteria in 
our AgNP resistant bacteria to determine if acquisition of this trait might potentially 
contribute to their potential biofilm formation. 
 3.3.3 AFM Image Bacterial Preparation 
Glass slides (Gerhard Menzel GmbH, Braunschweig, Germany) were sonicated 
for 5 min in acetone, ethanol, and DI water and dried with Nitrogen gas and then plasma 
cleaned for 3 min using PC-2000 Plasma cleaner (South Bay technology, San Clemente, 
CA ). The glass slides were coated with 0.01% poly-D-lysine with a molecular weight of 
70,000 to 150,000 and allowed to dry for 10 minutes (Chen et al., 2014).Deflection 
sensitivity and force constant were calculated and applied for the measurements using 
thermal calibration. The speed rate for the peizo was between 5 µm/S.  The range was 
between 1-3 µm and the measurement period was one second.  Each of the cells was 
measured 50 times. The surface deflection and adhesion forces were also measured and  
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calculated for all applied interventions. We used AFM Agilent model 5600LS. The force 
spectroscopy analysis was performed using R software RX64 3.0.2.The results are shown 
in figure 10.  
3.4 Growth Assays 
 The ability of the bacteria to grow in response to silver was determined by 
exposing them to varying concentrations of spherical silver nanoparticles of 10 nm and 
40 nm diameter sizes, and of different coating, citrate and PVP (obtained from 
NanoComposix, San diego, CA) and bulk silver nitrate (Fisher Scientific, Fair Lawn, NJ). 
We determined that the different-sized silver nanoparticles and bulk silver nitrate were 
effective over different concentration ranges replicating the findings of earlier researchers 
(e.g. Morones et al. 2005;(J. R. Morones et al., 2005) . Therefore we assayed the 
effectiveness of 10 nm particles at concentrations of 100 µg/l, 250 µg/l, 500 µg/l, 750 
µg/l, and 1000 µg/l. 40 nm particles were evaluated at 2000 µg/l, 4000 µg/l, 5000 µg/l, 
and 6000 µg/l. Bulk silver nitrate was evaluated at 50 µg/l, 100 µg/l, 250 µg/l, 500 µg/l, 
1000 µg/l, and 2000 µg/l.  
The control (C1 – C5) and treatment (T1 – T5) populations were cultured for a total 
of 305 generations.  Replicates were propagated by daily transfers of 0.1 ml of each 
culture into 9.9 ml of DMB, allowing populations sizes to fluctuate daily between 5 
*106 cells per ml at the transfer bottleneck to 5 *108 cells per ml, for a total of ~6.64 
generations of binary fission by 2 log10 increase of the cells/ml (Lenski et al. 1991).        
All silver treatments were compared to equivalent inoculates of bacteria growing 
in DMB medium without silver (control). Population growth in response to silver was  
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measured by optical density and by determining colony forming units (CFU) via serial 
transfer on DMB agar plates at 0 and 24 hours. Two plates were prepared for each 
treatment in each experiment. The optical density was determined as an estimate of the 
cell density of bacteria at 620 nm absorbance using a multi-mode single-channel 
monochromator-based microplate reader.  Optical density readings were taken at 0, 3, 6, 
12, and 24 hours of growth.  Optical density readings were recorded twice for each 
treatment in each experiment.  
Population samples of all 10 samples took at regular intervals between the 
sequential transfers. The optical density was accounted for the cell density measurement 
of bacteria at 620 nm absorbance using multi-mode single-channel monochromator based 
microplate reader. Colony forming Units (CFU) experiment using Davis minimum Agar 
plates were conducted for our 0 and hour 24 of each treatment (Bennett, Dao, & Lenski, 
1990) consecutive days. Once this had occurred, each control replicate (C1…C5) was 
divided in two, one portion will be designated as T1…T5.  A sample was kept in -80 
freezer for further analysis by following protocol: 
-   10 large and 10 small freezer vials were labelled.  
-   1 ml glycerol was added to each flask and mixed well  
-   1 ml to 1.5 ml centrifuge tubes and 5 ml to 15 ml centrifuge tubes were added 
and kept in appropriate freezer box   
Mean fitness of the stocks growing in different concentrations of silver (AgNPs 
and AgNO3) was measured at several generations.   This was accomplished by 
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measuring the survival and colony growth of treatment and control stocks in the 
presence of AgNPs and without them (ancestral environment.). 
3.5 Phenotyping Results  
Figure 1 shows population growth as measured by the mean optical density of the 
bacteria at generation 250 in the presence of 40 nm citrate-coated silver nanoparticles at 
varying concentrations for the treatment and control bacteria. The bacteria assayed in 
these figures represent a cocktail generated from mixing equal volumes of all five 
replicate lines of control and treatment (C1 – C5 and T1 – T5).  The mean standard 
deviation of all optical density measurements was 0.005.  Given these small values, none 
of the standard deviations are shown in there optical density figures.  Figure 1 shows that 
there is no apparent growth of the bacteria at any of the concentrations assayed (2000, 
4000, 5000, and 6000 µg/l) for control bacteria. In the treatment bacteria, there is 
significant growth for 2000 and 4000 µg/l as well as5000 µg/l especially at stationary 
phase. In figure 2, population growth of control and treatment bacteria exposed to 40 nm 
PVP coated silver nanoparticle is shown. In this figure, the treatment bacteria are shown 
to grow at hour 6 at all concentrations compare to controls.  The controls show slow 
growth after hour 12 and at hour 24. Figure 3 and 4 shows again that the treatment 
populations have higher growth in 10 nm citrate and PVP coated silver nanoparticles 
respectively relative to controls. In these figures, 1000 µg/l concentration of 10 nm citrate 
and PVP coated nanoparticles prevents growth in both strains. This demonstrates stronger 
antimicrobial effect of smaller size nanoparticles without coating effect considerations. 
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Figure 3 shows that citrate coated 10 nm AgNPs at eliminated growth in the control strain 
at concentrations > 250 µg/l; however the treatment populations were able to grow 
effectively (after a 6 hour lag) at concentrations up to and including 750 µg/l. At 1000 
mg/l growth was completely eliminated in the control, yet some modest growth was 
observed in the treatment population. Figure 4 demonstrated that 10nm PVP-coated 
AgNPs eliminate growth in the controls at concentrations > 250 µg/l.  There is an 
indication of some growth in the control population at 750 µg/l and no growth in the 
treatment at this concentration.  However, this result is entirely inconsistent with all other 
measurements, and could have resulted from an error in labeling.  Figure 5 shows the 
effect of bulk silver nitrate against the control and treatment populations by optical 
density measurements. At concentrations of 500 µg/l and greater there is no observed 
growth of control bacteria.  In the treatment population, growth is observed at 
concentrations > 250 – 1000 µg/l.   No growth is observed at 2000 µg/l.   Figures 6a-e are 
showing colony forming unit (CFU) log 10 differences between hour 0 and hour 24 of the 
two strains across concentrations using nonlinear log regression. More than 5 log 
reduction was observed using 10 nm citrate coated silver nanoparticles on control 
bacteria and this reduction was less than 3 log 10 CFU for 10 nm PVP coated.  In 
treatment bacteria 10 nm citrate and PVP coated nanoparticles results were somewhat  
similar to each other.  There was a less than 3 log 10 CFU on both PVP and citrate coated 
10 nm particles.  Due to the fact that 40nm AgNPs are much less effective than the 10nm 
size, a much higher concentration is required to achieve anti-microbial effects (Tajkarimi 
et al. 2014.)  In 40 nm citrate coated bacteria, control bacteria showed significant higher 
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(more than 3 log 10 CFU) antimicrobial effect at 6000 g/L concentration compared to 
the same size PVP coated particles.  In treatment population bacteria there was not a 
significant difference between citrate and PVP coated bacteria at all concentrations 
assayed. Bulk silver nitrate showed more than 5 log reductions at 1000 µg/l concentration 
and about 3 log10 reduction for the treatment populations. Table 3 compares the relative 
effectiveness of bulk silver, 10nm citrate-coated, and 10nm PVP-coated bacteria by CFU 
reduction from 100 – 500 µg/L.  The average reduction for 10nm citrate-coated AgNPs > 
bulk silver > 10nm PVP-coated over this concentration range for both controls and 
treatment populations.   
Table 4 shows the minimum inhibitory concentrations (MIC) as determined by 
the microdilution test at generation 300 for the control and treatment replicates (C1—C5 
and T1—T5).  The MICs were determined for five forms of silver; 10nm citrate-coated 
AgNPs, 10nm PVP-coated AgNPs, 40nm citrate-coated AgNPs, 40 nm PVP-coated 
AgNPs and bBulk silver nitrate (AgNO3). Due to the way the MICs are determined, some 
of the values read as a range (e.g. 10 – 25 mg/L) or as an inequality (> 25 mg/L).  For 
statistical analysis, is a range was determined, the mean value was used in the calculation.  
If an inequality was determined, than a minimal integer value greater than the inequality 
was used (so > 25, became 26 in the calculation.)  The latter method is statistically 
conservative.  For the 10nm citrate-coated and 10nm PVP-coated AgNP MIC’s the mean 
MIC of the treatment populations were statistically significantly different from the 
controls as tested by nested ANOVA; F = 66.61, p < 0.0001; and F = 8.65, p < 0.019 
respectively.  In the case of the 40nm citrate-coated AgNP MICs the mean MIC of the 
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treatment populations were statistically significantly different from the controls; F = 
101.44, p < 0.0001.  No test was performed to determine the MIC of 40nm PVP-coated 
AgNPs (none were available.)  Finally, for bulk silver the mean MIC of the treatment 
populations were also statistically significantly different from the controls; F = 101.44, p 
< 0.0001.  The values in table 4 show that the ratios of difference for the silver forms by 
treatment compared to control populations were 10nm citrate-coated (4.66); 10nm PVP-
coated (1.44); 40nm citrate-coated (1.70); and bulk silver (26.2)!    
Figure 7a and b show Scanning Electron Microscope (SEM) images of treated and 
non-treated bacteria with 40 nm PVP-coated silver nanoparticles. Figure 7b illustrates 
coagulations of silver nanoparticles on the surface of bacteria compared to non-treated 
bacteria. Figure 8a and b compare the AFM image of control bacteria in the presence of  
bacterial with AgNPs. This image was taken using the tapping mode (Terri A. Camesano, 
1995).  Both of these images illustrate association of silver nanoparticles with the 
bacterial cell wall compared to the control treatment without silver nanoparticles. The 
AFM image of the treated cell shows apparent damage to the cell wall compared to the 
untreated control. 
Figure 9 shows the disc diffusion assay results comparing standardized control 
treatment population E. coli exposed to different concentrations of 10 nm citrate coated 
AgNPs as well as 30 µg chloramphenicol disks as a positive control. The control 
populations are equally inhibited by both concentrations of AgNPs in the solid medium.  
However, the treatment populations show a smaller zone of inhibition compared to  
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control populations at both concentrations.  In addition the inhibition zone for the 
treatment populations is smaller at the lower concentration.  In addition the zone of 
inhibition caused by the chloramphenicol seems to be larger in the treatment population 
disk.  
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CHAPTER IV 
 
GENOMICS OF SILVER NANOPARTICLE RESISTANCE 
 
 
 Whole genome resequencing was utilized to identify genomic variants associated 
with the greater AgNP and bulk silver resistance of the treatment populations compared 
to the controls.  This technique has been used by other researchers to identify genomic 
variants generated from laboratory experimental evolution in E. coli (e.g. Herring et al. 
2006; Barrick and Lenski 2009).  DNA was extracted from each replicate population 
(generation 100, generation 150, generation 200) that had been stored in the -80ºC freezer 
(C1 – C5; T1 – T5) as well as from the ancestral population E. coli K12 MG1655 obtained 
from ATCC (designated C0) for the genomic studies. The sample of cells used for 
extraction came after each population was allowed to grow for 24 hours in standard DM 
broth (without AgNPs).  Cell density was approximately 108 cells/ml.  Extraction of 
DNA followed the protocol from Nucleic Acid Sample Preparation for Downstream 
Analysis: Principles & Methods (GE Health Life Sciences, 2014: 
http://www.gelifesciences.com/webapp/wcs/stores/servlet/catalog/en/GELifeSciences-
US/applications/nucleic-acid-sample-preparation/ ).  DNA from generation 150 (C1—C5; 
T1—T5) as well as the ancestral population (C0) was sent to the Michigan State 
University core sequencing facility.  There genomic libraries were prepared for Illumina 
sequencing, and these were sequenced on an Illumina HiSeq 2000 platform.  In the first 
run, average read coverage was between 16.2 – 42.7X.  For this reason, G150 DNA was 
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sequenced again to improve the coverage to between 40 – 60 X for all reads.  The data 
reported in this study for G150 are from the 2nd run. 
The generation 100 and 200 samples were sequenced at the JSNN on our Illumina 
MiSeq sequencing platform.  The quantity of the extracted DNA (at least 3 ng per 
sample) was assessed using our Promega Quantus™ Fluorometer.  This quantity is 
required to use the Illumina Nextra XT kit for preparing the genomic library for 
sequencing. The Illumina Nextera XT kit prepares fragments of DNA that range from 
about 250—1,500 base pairs (bps) long.  The fragments are then ligated to adapters that 
both connect the DNA to the MiSeq flow cell and include a DNA sequence that 
“barcodes” the sample for later identification.  Finally before sequencing the genomic 
library fragment lengths must be quantified.   This was accomplished by use of the 
Agilent Bioanalyzer.  The bioanalyzer demonstrated that our genomic libraries fit the 
requirements for an effective run of the MiSeq sequencing platform.  The genome size of 
E, coli K12 MG1655 is listed at 4,641,653 bps and is a circular single-stranded DNA 
chromosome (http://www.ncbi.nlm.nih.gov/nuccore/U00096.3 ) The MiSeq sequencing 
platform sequenced both the generation 100 and 200 samples in about 24 hours each.  
The sequence reads were deposited in our Illumina Basespace@ account in both .fastq 
and .bam formats. 
Prior to sequence alignment and variant calling, the Illumina adapter sequences 
must be removed from the MiSeq reads.  This was accomplished via the use of Partek.  
Partek is an enterprise level bioinformatics tool.   North Carolina A&T State University  
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version of this program is maintained by Dr. Scott H. Harrison of the Biology 
department.  Sequence alignment and variant calling from the generation 100 and 200 
samples was achieved by use of the breseq 0.24rc6 pipeline developed by the Barrick 
Laboratory at the University of Texas 
(http://barricklab.org/twiki/bin/view/Lab/ToolsBacterialGenomeResequencing). This 
pipeline has been used in a number of genomic studies of bacteria (Barrick and Lenski 
2009; Deatherage and Barrick 2014).  The breseq program is a computational pipeline for 
finding mutations relative to a reference sequence in short-read DNA re-sequencing data 
for microbial sized genomes. The breseq program is a command line tool implemented in 
C++ and R.  The pipeline accomplishes alignment to the reference genome via the 
Bowtie 2 algorithm and calls variants via the Sequence Alignment Map (SAMtools) 
algorithm.  Both Mr. Tajkarimi and Dr. Graves received training on the use of this 
pipeline directly from Dr. Jeffrey Barrick (a collaborator through the Biocomputational 
Evolution in Action, BEACON National Science Foundation Science Technology 
Center.)  The breseq program is capable of identifying genomic variants including single 
nucleotide polymorphisms (SNPs), indel (insertion-deletion polymorphisms), and 
insertion elements (IS, transposons). 
Table 5a, b show the genomic variants that exist in the ATCC@ strain of E. coli 
K12 MG1655 compared to the reference genome.  There are 3 point mutations, 3 
deletions (one large 776 bps), and 2 insertions.  The 776 bp deletion in the crl gene at 
position 257,908 was found in all reads, and thus can be inferred to be fixed in this strain  
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of MG1655. Also fixed are the deletions in the gatC pseudogene, and the insertions at the 
intergenic positions 3,560,455 and 4,296,380.  Table 6a, b shows the genetic variants 
compared to the reference genome in the control populations (C1—C5) at generation 100. 
These variants were called in breseq’s consensus mode.  Consensus mode only calls 
variants that are fixed in the reads (seen in all reads at that position.)  The polymorphism 
mode calls many more variants; the vast majority of these are at very low frequency 
(~0.001 – 0.01).  Mutations at very low frequency are most likely the result of genetic 
drift and not natural selection therefore are not of interest in attempting to reveal the 
genomic basis of adaptation to any specific environment.  Four of the ancestral mutations 
were called (deletions in crl, and gatC; insertions in the intergenics).  However, new 
mutations are also called at generation 100 in the control populations.  Three of these 
mutations are found in three or more populations and thus likely represent adaptations 
(1,999 bp deletion between ychE and oppA; 776 bp deletion in insB-insA; and 4 bp 
insertion in insA-uspC.)  There are an additional three mutations that are unique to 
specific replicate (most likely representing genetic drift, insertion element adding 9 bps to 
ybhl; insertion element adding 4 bps to menC; and a point mutation in rpoA.) Table 7a, b 
shows the genomic variants called in the treatment populations (selected for AgNP 
resistance) in generation 100.  The treatment populations retained four of the ancestral 
mutations (same as controls).  In addition, there were three mutations that were identical 
to the control populations (oppA, insB1-insA, insA—uspC; thus most likely related to 
shared features of the culture regime).  However the remaining mutations were unique to  
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the treatment populations (point mutation in cusS, at position 593497; point mutation 
intergenic at position 3,815,808 between pyrE and rph; and a point mutation in rpoB at 
position 4,182,803).  The latter mutation was shared by four of the five replicates. Table 
8a, b shows the genomic variants called in both the control and treatment populations in 
generation 150.  Generation 150 reads were generated from the Michigan State 
University sequencing center on the Illumina HiSeq 200.  However the reads showed 
high consistency with those generated on the JSNN’s MiSeq system.  The generation 150 
data showed 13 mutations that were probably ancestral (shared by both controls and 
treatment populations, many of these matched the ancestral mutations that had been 
identified from the generation 100 sequencing.)  Two of the mutations were control 
adaptations shared by the control populations; seven mutations were unique to specific 
control populations.  Ten unique mutations were identified in the treatment populations.  
Of these mutations, 8 were found in the T3 replicate, 1 in T1, and 1 in T5.  Of the 
mutations in the T3 replicate, the mutations in cusS, purL, rpoB, and ompR are most 
interesting (as subsequent analysis of generation 200 variants revealed.)  Table 9a, b 
show the genomic variants called in both control and treatment populations for generation 
200.  Four of the ancestral mutations are scored for both control and treatment 
populations, three mutations are shown that are shared by both control and treatment 
populations (these were scored in previous generations), one shared mutation in the 
controls (RNA polymerase C, position 4,186,532), and two unique to control replicates 
(ccmE, position 2,295,168 and rpoA, position 3,440,459.)  The silver resistant mutations  
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shared by all replicate treatment populations were cusS, position 593,467 first scored in 
replicate T4 in generation 100 and rpoB, position 4,182,820, first called in replicate T3 in 
generation 150. In addition, the mutation in purL at 2,694,130 is shared by 4 of the five 
treatment replicates.  This mutation was also first called in replicate T3 in generation 150.  
There are also 3 unique indel mutations in T1, T2, T5 in ompR (positions 3,536,265; 
3,536,342; and 3,536,570.) 
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CHAPTER V 
 
DISCUSSION AND SIGNIFICANCE 
 
 
 Engineered metallic and metallic oxide nanomaterials are being used in an 
increasing number of applications.  Models suggested that the concentration of silver 
nanoparticles found in European surface waters in 2009 was 0.088 mg/L/year (Gottschalk 
et al. 2009.)  Historical evidence that agriculture and aquaculture are fertile grounds 
driving the evolution of both heavy metal and antibiotic resistance (Seiler and Berendonk 
2012.)   Previous research concerning heavy metal resistance in bacteria has not focused 
on resistance to nano-metals (Silver and Phung 2005; Mijnendonckx et al. 2013.)  So far 
there is only one report in the literature describing the isolation of nanosilver resistant 
bacterium.  This study (Gunawan et al. 2013) accidentally isolated a resistant bacterium 
in a culture of E. coli that became contaminated with a Bacillus sp. of unknown origin.  
They reported that the Bacillus sp.  was nanosilver resistant.  This study specifically 
evolved resistance to 10nm citrate-coated nanoparticles and tested the resistant bacteria 
against a variety of nanoparticles and bulk silver nitrate. 
This project was motivated by the fact that antimicrobial resistance is a growing 
worldwide public health issue for humans.  Drug and antiseptic resistant (MDR) bacteria 
are contaminating food and causing dangerously untreatable clinical infections. This 
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situation requires novel treatment strategies to control MDR pathogenic microorganisms 
(Chait et al., 2012; Durso et al., 2012; Mellata, 2013)  As silver nanoparticles are being 
proposed as the new antidote for such bacteria (e.g. Lara et al. 2011; Rai et al. 2012)  it is 
a crucial to determine how quickly and effectively bacteria can evolve resistance to them.  
To address this possibility this study utilized laboratory experimental evolution with 
Escherichia coli as a model system (Tyerman et al., 2013).  Experimental evolution has 
been used to show genomic changes in E. coli both on short long term time scales 
(Lenski and Travisano 1994; Herring 2006.) 
Silver and Phung (2005) showed that such heavy metal transporting mechanisms 
are widespread in bacteria. E. coli K12 MG1655 was chosen because it genome has been 
fully sequenced and does not normally carry silver resistance genetic elements (sil.)   
Bacteria with such elements can show 100-fold greater MICs than those without (Silver 
and Phung 2005; Mijnendonckx 2013).  However, E. coli K12 MG1655 does not some 
genetic elements that have been associated with heavy metal resistance. For example, 
copA (position 510,603—508,099), that codes for the p-type ATP-ase which inducible in 
the presence of either copper or silver, catalyzes the efflux of both metals. Also, cusS has 
been shown to be involved in effluxing both copper and silver (Munson et al. 2000; 
Franke, Grass, and Nies 2001; Gudipathy and McEvoy 2014).   
Li et al. 1997 was an earlier experiment that isolated silver resistant E. coli 
mutants on solid media.  This experiment utilized bulk silver nitrate (AgNO3) and silver 
sulfadiazine (AgSD.) They were able to increase the silver resistance of the mutant 
strains by 128 times for (AgNO3) and 64 times for (AgSD).  They also noted that their 
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silver resistant mutants had reduced susceptibility to cephalosporins (4 fold decrease in 
MICs); and possibly tetracycline and chloramphenicol.  This result suggests that their 
mutants were pleiotropic (affecting more than one trait simultaneously.)  This study was 
conducted before the wide spread availability of whole genome sequencing, but they 
were able to use protein-gel electrophoresis to show that their mutant strains were 
deficient in the activity of the proteins OmpF, OmpC, and OmpA.  These proteins are 
called “porins” and they influence the permeability of the bacterial outer membrane. Li et 
al. 1997 concluded that the resistance of these mutants to Ag+ and antibiotics was due to 
decreased permeability of the outer membrane to these substances. 
           This study showed that by generation 250 the treatment bacteria had greater AgNP 
as well as bulk silver (AgNO3) resistance at a range of concentrations compared to the 
controls.  The minimum inhibitory concentrations at generation 300 showed that 
treatment replicates had greater silver resistance for all types of silver measured (Table 
4a,b).  In addition by generation 305 that the treatment populations had increased their 
bulk AgNO3 resistance by ~ 100x at 100 µg/l relative to the controls and ~10X at 250 
µg/L relative to the controls (Figures 6a--e.)  The resistance to AgNPs depended on size 
and coating.  However, the treatment populations performed better than the controls 
across the range of concentrations studied (Table 3, Figures 6a—e).  These results 
indicate that the selection protocol produced bacteria that were resistant to both AgNPs 
and bulk silver.  It is still unclear whether these resistances differ.  Some studies suggest 
that the mechanism of action for metallic nanoparticles are only due to the release of the 
metal ion (Xiu et al. 2012); while others suggest that the particle itself may play a role 
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independent from the coating type (Bandyopathy et al. 2012). Our laboratory is currently 
engaged in research that will further separate metal ion from nano-size effects. 
The genomic analysis allows us to observe the increase in silver resistance 
mutants from the ancestral population (C0), through treatment populations from 
generations 100, 150, and 200.  Unfortunately time and funding did not allow us to 
sequence generation 250 or 300.   Therefore it is possible and even likely that additional 
silver resistance mutations had accumulated in the treatment populations in the period 
between the sequencing and the last phenotyping (G300). However the genomic analysis 
makes clear that the treatment populations had accumulated three major mutations by 
generation 200 that partially accounts for their greater silver resistance (cusS, 593,467, 
T—G, D435A or aspartate (electrically charged -) to alanine (hydrophobic) at position 
435; purL, 2,694,130, G—T, R191C or Arginine (electrically charged +) to Cysteine 
(hydrophilic); and rpoB, 4,182,820, C—T, H526Y or histidine (electrically charged +) to 
tyrosine (hydrophilic).  The cusS mutation occurs within the histidine-kinase, DNA 
gyrase B, and HSP90-like ATPase site of the protein (ecogene; http://www.kegg.jp/ssdb-
bin/ssdb_motif?kid=eco:b0570).  The purL mutation occurs within prior to the enzyme’s 
active sites (257—389; 432—589; and 822—966; ecogene, http://www.kegg.jp/ssdb-
bin/ssdb_motif?kid=eco:b2557).  The rpoB mutation occurs within the Rpb2 domain 3 
site of the RNA polymerase B (ecogene; http://www.kegg.jp/ssdb-
bin/ssdb_motif?kid=eco:b3987).  Thus all of these mutations are non-synonymous and 
two of them occur within an active site of a protein.   
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The identification of a mutation in cusS that contributes to AgNP resistance in the 
treatment lines is not surprising.  This is supported by its known function and previous 
experiments (Lok et al. 2008; Gudipathy and McEvoy 2014).  However, this specific 
mutation has not been reported before.  The purL (phosphoribosylformyl-glycineamide 
synthetase) gene plays a role in purine synthesis (Sampei and Mizobuchi 1989).  Its 
mechanistic relationship to silver resistance is not immediately clear.  Mutations in the 
rpoB (RNA polymerase B) gene have been linked with antibiotic resistance (Romero and 
Casedsús 2014) as well as increased evolvability (Barrick et al 2013.)  Both of these traits 
could conceivably contribute to silver AgNP or AgNO3 resistance.  This result 
specifically predicts that these mutations may be pleiotropic, thus it is likely that the 
AgNP resistant bacteria could be resistant to other environmental insults, including 
antibiotic resistance.  Subsequent experiments will be required to test these possibilities. 
 In conclusion, this study has shown that bacteria are capable of rapidly evolving 
de novo resistance to AgNPs (~250 generations or about 38 days.)  This experiment 
cannot determine if the resistance resulted from a “hard” or “soft” sweep of mutations.  A 
hard sweep results from de-novo mutations starting at very low frequency and then 
sweeping to fixation in a specific environment.  Soft sweeps begin with existing genetic 
variants that are maintained in the population at very low frequency.  While none of the 
high frequency mutations scored in the treatment populations (T1—T5) at generation 200 
were found in the ancestral lines (C0); this does not mean that they were not there at 
frequencies undetectable by our sequencing.  In addition, there is evidence that the 
process of cocktailing the treatment populations in generation 140 may have led to a 
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“sweep” by the T3 replicate in the treatment populations.  T3 was the only population that 
had all three of the cusS, purl, and rpoB mutations.  Finally, given that we did not 
sequence generation 250 and 300, we do not know if additional mutations at low 
frequency did not sweep to consensus.  This will be tested in subsequent studies.  In 
addition, Figure 8 shows via atomic force microscopy (AFM) that there seems to be clear 
physical differences in the cell wall characteristics of the control and treatment lines by 
generation 250.  It seems unlikely that such strong phenotypic differences are caused by 
only three point mutations.  This suggests that in addition to the genomic differences we 
measured between the control and treatment populations that there may be transcriptomic 
differences as well.   For example, Lok et al. 2010 utilizing the silver resistant mutants 
first scored by Li, Hiroshi, and Williams (1997) showed significant gene expression 
pattern differences in the mutant strains compared to controls by two-dimensional gel 
electrophoresis and mass spectrometry.  Future studies in the experimental evolution of 
silver nanoparticle resistance will need to utilize RNAseq methods in addition to genomic 
resequencing to more fully understand the mechanisms of resistance. 
The rapid evolution of silver nanoparticle resistance in an “off the shelf” 
laboratory bacterium does not bode well for the sustainability of silver nanoparticles in 
antimicrobial applications.  Table 1 shows that E. coli K12 MG1655 had few resistance 
elements of any kind.  Yet we know that silver resistant bacteria already exist in nature 
(Mijnendonckx 2013; Graves 2014).  Zhang, Liang, and Hu 2013 have shown the 
increase in expression of the silE gene in bacterial communities isolated from sludge 
water in a bioreactor system.  Silver resistance as well as antibiotic resistance is carried 
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on plasmids.  This means that they can be horizontally transmitted between widely 
separated groups of bacteria.  Indeed, nanoalumina has been demonstrated to increase the 
rate of plasmid transfer (Qiu 2012).  It is not known whether other nanometals would 
have this effect.   
 This means that there is a crucial need for more studies of the impact of metallic 
or metallic oxide nanoparticles on a wider variety of bacteria and bacterial communities.  
For example, given that the mechanisms of antibiotic and metal resistance are often 
shared, it might not take MDR bacteria long to evolve resistance of metallic 
nanoparticles.  Should this occur, the use of metallic nanoparticles would enter a cycle of 
increasing concentration to effect desired result (a treadmill, similar to that observed in 
pesticide and antibiotic use.)  Given that the attractiveness of metallic and metallic oxide 
nanoparticles results from their current effectiveness against bacteria at low concentration 
along with their low toxicity against mammalian cells in their effective range, increasing 
resistance would eliminate their usefulness. 
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APPENDIX A 
TABLES AND FIGURES 
 
 
Table 1. Antimicrobial Genes in Escherichia coli 
  
Antimicrobial Agent Gene/s MG1655 Reference 
Streptomycin aadA1 no Momtaz et al. 2012 
Gentamicin aac(3)-IIV no 
Sulfonamide sul1, bla SHV, bla, CMY no 
Beta lactams kpc, cmy-2, shv, tem no Xia et al. 2011 
ctx-m, lap-1, bla-tem no 
Ampicillin ere(A) no 
Erythromycin cat A1 no Momtaz et al. 2012 
Chloramphenicol cm1A no 
Tetracycline tet(A), tet(B) no 
Trimethoprim dfr A1 no 
Quinolones qnr A no 
Sulfonamide sul1, sul2  no Tadesse et al. 2012 
Silver silE, sil-CFBA no 
Gupta et al. 2001; Silver 
2003 
 cusS, ompA, ompB, ompF yes 
Li et al. 1997; Gudipathy & 
McEvoy 2014 
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Table 2. Directional Selection for AgNP Resistance 
 
Generations Exposure 
Concentration 
1 – 50 50 µg/l 
51 -- 140 100 µg/l 
141 – 265* 125 µg/l 
           266– 305       125 µg/l 
 
*Replicates were mixed at generation 141 to rescue poor performing populations;  
samples were taken from the cocktail to reestablish five replicates. 
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Table 3. Relative Effectiveness of Silver by 
Type (measured by CFU reduction)                   
 
 Control 
         Bulk 10-citrate 10-PVP 
     Conc. 
100 -1.00 -1.50 0.50
250 -1.00 -2.25 -0.25
500 -1.75 -2.20 -0.75
Mean -1.25 -1.98 -0.17
SD 0.43 0.42 0.63
Treatment
          Bulk 10-citrate 10-PVP 
Conc. 
100 1.00 -1.50 1.00
250 -0.75 -2.00 1.00
500 -0.75 2.70 0.25
Mean -0.17 -0.27 0.75
SD 1.01 2.58 0.43
 
The relative effectiveness of bulk silver, 10nm citrate-coated AgNPs, and 10nm PVP-
coated AgNPs are estimated by CFU reduction of control and treatment populations 
across three concentrations (100 – 500 g/L.)  These data suggest that effectiveness 
should be ranked 10nm citrate-coated > bulk silver > 10nm PVP-coated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
Table 4a. Minimum Inhibitory Concentration Determined by Micro Dilution 
Method at Generation 300 
 
 
 
 
 
 
10nm Citrate Coated NPs  10nm PVP Coated NPs  
C1 5 mg/L T1 >50 mg/L C1 10 mg/L T1 >25 mg/L 
C2 5 mg/L T2 7.5 mg/L C2 10 mg/L T2 17.5 mg/L 
C3 5 mg/L T3 >50 mg/L C3 10-25mg/L T3 >25 mg/L 
C4 5-7.5 mg/L T4 7.5 mg/L C4 10-17.5 mg/L T4 17.5 mg/L 
C5 5 mg/L T5 7.5 mg/L C5 >25 mg/L T5 >25 mg/L 
      
Mean  5.25 mg/L  24.5 mg/L Mean 15.25 mg/L  22 mg/L 
Std. 
Dev. 
0.56  23.27 Std. 
Dev. 
6.27  4.10 
40nm Citrate Coated NPs Bulk Silver Nitrate (AgNO3) NPs 
C1 125 mg/L T1 250 mg/L C1 0.625mg/L T1 25 mg/L 
C2 125 mg/L T2 125 mg/L C2 0.625mg/L T2 0.625 mg/L 
C3 87.5 mg/L T3 250 mg/L C3 0.625mg/L T3 25 mg/L 
C4 125 mg/L T4 125 mg/L C4 0.625mg/L T4 12.5 mg/L 
C5 125 mg/L T5 250 mg/L C5 0.625mg/L T5 12.5-25 mg/L 
Mean  117.5 mg/L 200 mg/L Mean 0.625 mg/L 16.375 mg/L 
Std. 
Dev. 16.77 68.46 
Std. 
Dev. 0.00 10.21 
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Table 4b. Ratio of Treatment to Control Minimum Inhibitory Concentration (MIC) 
by Type of Silver Generation 300 
 
Type Ratio (T/C) F p 
10 nm Citrate-
coated 
4.66 – 3.04 X 3.328 < 0.106 ns 
10 nm PVP-coated 1.65 – 1.44 X 5.608* < 0.045 
40 nm Citrate-
coated 
1.70 X 6.849* < 0.031 
Bulk AgNO
3
 26.2 X 11.64** < 0.009 
 
 
Table 5a. Genomic Variants in Ancestral ATCC@ 
E. coli K12 MG1655 
 Position Mutation Freq. 
[crl] 257,908 Δ776 bp 1.000
ylcI ← 580,302 C→T 0.222
gatC ← 2,173,361 Δ2 bp 1.000
gshA ← 2,815,694 A→T 0.182
garK ← 3,271,022 Δ3 bp 0.075
glpR ← / ← glpR 3,560,455 i+G 1.000
gltP → / ← yjcO 4,296,060 C→T 0.333
gltP → / ← yjcO 4,296,380 +CG 1.000
 
Mutation Description:  = deletion; i = insertion;             = point mutation 
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Table 5b. Genomic Variants in Ancestral ATCC @E. coli K12 MG 1655 
(Annotation and Description) 
 
Annotation  Description 
[crl]  [crl] 
ylcI ← R48R (AGG→AGA)  
DUF3950 family protein, 
DLP12 prophage 
gatC ← pseudogene (1-2/442 nt) 
pseudogene, 
galactitol-specific enzyme 
IIC component of PTS* 
gshA ← L249H (CTT→CAT)  glutamate-cysteine ligase 
garK ← coding (747-749/1146 nt) glycerate kinase I 
glpR ← / ← glpR intergenic (-2/+1) 
pseudogene, DNA-binding 
transcriptional repressor* 
gltP → / ← yjcO intergenic (+266/+376) 
glutamate/aspartate:proton 
symporter/Sel1 family 
TPR-like repeat protein 
gltP → / ← yjcO intergenic (+586/+56) 
glutamate/aspartate:proton 
symporter/Sel1 family 
TPR-like repeat protein 
Annotation  Description 
[crl]  [crl] 
ylcI ← R48R (AGG→AGA)  
DUF3950 family protein, 
DLP12 prophage 
gatC ← pseudogene (1-2/442 nt) 
pseudogene, 
galactitol-specific enzyme 
IIC component of PTS* 
gshA ← L249H (CTT→CAT)  glutamate-cysteine ligase 
garK ← coding (747-749/1146 nt) glycerate kinase I 
glpR ← / ← glpR intergenic (-2/+1) 
pseudogene, DNA-binding 
transcriptional repressor* 
gltP → / ← yjcO intergenic (+266/+376) 
glutamate/aspartate:proton 
symporter/Sel1 family 
TPR-like repeat protein 
gltP → / ← yjcO intergenic (+586/+56) 
glutamate/aspartate:proton 
symporter/Sel1 family 
TPR-like repeat protein 
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Table 6a. Genomic Variants in E. coli K12 MG1655 (Control Populations) 
Generation 100 
 
Populations Gene Position Mutation 
C0, C1, C2, C3, C4, C5 [crl] 257,908 Δ776 bp 
C1, C2 ybhI → 802,819 IS1 (+) +9 bp 
C2, C3, C4 
ychE → / → 
oppA 1,299,499 Δ1,199 bp 
C1, C2, C3, C5 insB1–insA 1,978,503 Δ776 bp 
C1, C2, C3, C4, C5 insA ← / → uspC 1,979,486 IS5 (+) +4 bp 
C0, C1, C2, C4, C5 gatC ← 2,173,361 Δ2 bp 
C4 menC ← 2,375,828 IS186 (+) +4 bp 
C1 rpoA ← 3,440,459 G→A 
C0, C1, C2, C3, C4, C5 glpR ← / ← glpR 3,560,455 +G 
C0, C1, C2, C3, C4, C5 gltP → / ← yjcO 4,296,380 +CG 
Evaluation 
Probably ancestral 
Control Adaptation 
Control Unique  
Adaptation Ag Resistant 
Unique Ag resistant 
 
Genomic variants were called in consensus mode; thus all have a frequency of 1.00 in 
their specific population.  Mutation Description:  = deletion; i = insertion;             = 
point mutation 
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Table 6b. Genomic Variants (Annotation and Description) Control Populations, 
Generation 100 
 
Gene Annotation Description 
[crl]   [crl] 
ybhI → coding (933-941/1434 nt) putative transporter 
ychE → / → oppA intergenic (+254/-485) 
UPF0056 family inner membrane 
protein/oligopeptide transporter subunit 
insB1–insA   insB1, insA 
insA ← / → uspC intergenic (-271/-264) IS1 repressor TnpA/universal stress protein 
gatC ← pseudogene (1-2/442 nt) 
pseudogene, galactitol-specific enzyme IIC 
component of PTS* 
menC ← coding (132-135/963 nt) O-succinylbenzoyl-CoA synthase 
rpoA ← R191C (CGT→TGT)  RNA polymerase, alpha subunit 
glpR ← / ← glpR intergenic (-2/+1) 
pseudogene, DNA-binding transcriptional 
repressor; regulator* 
gltP → / ← yjcO intergenic (+586/+56) 
glutamate/aspartate:proton symporter/Sel1 
family TPR-like repeat protein 
 
*Abbreviated description, color scheme denote evaluations from Table 6a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
Table 7a. Genomic Variants in E. coli K12 MG1655 (Treatment Populations) 
Generation 100 
 
Populations Gene Position Mutation 
T1, T2, T3, T4, T5 [crl] 257,908 Δ776 bp 
T4 cusS ← 593,467 T→G 
T3 ychE → / → oppA 1,299,499 Δ1,199 bp 
T1, T2, T3, T4 insB1–insA 1,978,503 Δ776 bp 
T1, T2, T3, T5 insA ← / → uspC 1,979,486 IS5 (+) +4 bp 
T1, T2, T3, T4, T5 gatC ← 2,173,361 Δ2 bp 
T1, T2, T3, T4, T5 glpR ← / ← glpR 3,560,455 +CG 
T3 pyrE ← / ← rph 3,815,808 A→C 
T2, T3, T4, T5 rpoB → 4,182,803 C→A 
T1, T2, T3, T4, T5 gltP → / ← yjcO 4,296,380 +CG 
 
Evaluation 
Probably ancestral 
Control Adaptation 
Control Unique  
Adaptation Ag Resistant 
Unique Ag resistant 
 
Mutation Description:  = deletion; i = insertion;             = point mutation 
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Table 7b. Genomic Variants (Annotation and Description) Treatment Populations, 
Generation 100 
 
Gene Annotation Description 
[crl]   [crl] 
cusS ← D435A (GAC→GCC)  
sensory histidine kinase in 
two-component regulatory system with 
CusR, senses copper ions 
ychE → / → oppA intergenic (+254/-485) 
UPF0056 family inner membrane 
protein/oligopeptide transporter subunit 
insB1–insA   insB1, insA 
insA ← / → uspC intergenic (-271/-264) 
IS1 repressor TnpA/universal stress 
protein 
gatC ← pseudogene (1-2/442 nt) 
pseudogene, galactitol-specific enzyme 
IIC component of PTS* 
glpR ← / ← glpR intergenic (-2/+1) 
pseudogene, DNA-binding 
transcriptional repressor;regulator* 
pyrE ← / ← rph intergenic (-40/+26) 
orotate 
phosphoribosyltransferase/ribonuclease 
PH (defective)* 
rpoB → P520Q (CCG→CAG)  RNA polymerase, beta subunit 
gltP → / ← yjcO intergenic (+586/+56) 
glutamate/aspartate:proton 
symporter/Sel1 family TPR-like repeat 
protein 
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Table 8a.  Genomic Variants in E. coli K12 MG1655 (Control and Treatment 
Populations) Generation 150. 
 
Populations Gene Pos. Mutation 
C1, C2, C3, C4, C5, T2, T3, T4 [crl] 257,906 Δ776 bp 
C3, C4 cynR ← 357,104 T→C 
C0, C4? cynR ← 357,114 C→A 
C0?, C1, C2?, C3?, C4?, C5? yaiX ← 381,337 IS2 (–) +5 bp 
C1 insD1 → 382,113 IS2 (–) +5 bp 
C0, C's and T's ylbE → 547,694 A→G 
C0, C's and T's ylbE → 547,835 +G 
T3 cusS ← 592,690 T→G 
T3 cusS ← 593,467 T→G 
C0, C2?, C5? insB1–insA 1,976,527 Δ776 bp 
C0, C1, C3, C4 insA ← / → uspC 1,977,510 IS5 (+) +4 bp 
C2, C3, T4 insB1–insA 1,978,503 Δ776 bp 
C1, C2, C3, C5, T2, T3, T4 insA ← / → uspC 1,979,486 IS5 (+) +4 bp 
T1, C2? wbbK ← 2,102,274 G→A 
T1 wbbK ← 2,104,250 G→A 
C1, C2 , C3, C4, C5, T1, T2, T3, 
T4 gatC ← 2,173,361 Δ2 bp 
T3 purL ← 2,692,152 G→T 
T3 purL ← 2,694,130 G→T 
T3 ompR ← 3,534,074 Δ57 bp 
T3 ompR ← 3,536,052 Δ57 bp 
C1, C2, C3, C4, C5, T1, T2, T3, 
T4 glpR ← / ← glpR 3,560,455 +G 
C0, C1, C2, C3, C4, C5 ppiC ← / ← yifN 3,957,957 C→T 
C3, C4, C5, T3 rhaM ← 4,093,134 T→G 
T3 rpoB → 4,180,843 C→T 
T3 rpoB → 4,182,820 C→T 
C0, C1, C2, C3, C4, C5 rpoC → 4,184,555 A→G 
C1, C2, C3, C4, C5, T1, T2, T4 rpoC → 4,186,532 A→G 
C0, C1, C2, C3, C4, C5 gltP → / ← yjcO 4,294,404 +GC 
C1, C2, C3, C4, C5, T1, T2, T3, 
T4 gltP → / ← yjcO 4,296,380 +CG 
C1 sgcR ← 4,526,151 IS5 (+) +4 bp 
C1, C5, T2 bglJ → 4,604,344 C→T 
T5 nadR → / ← yjjK 4,626,672 A→C 
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Ancestral 
Unique Control 
Control Adaptation 
AgNP resistant 
Unique AgNP 
 
Mutation Description:  = deletion; i = insertion;             = point mutation 
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Table 8b. Genomic Variants (Annotation and Description) Treatment and Control 
Populations, Generation 150. 
 
Gene                           Annotation                                                Description 
[crl]     [crl] 
cynR ←  K271E (AAA→GAA)  
transcriptional activator of cyn operon; 
autorepressor 
cynR ←  L267F (TTG→TTT)  
transcriptional activator of cyn operon; 
autorepressor 
yaiX ←  pseudogene (756‐760/2029 nt) 
pseudogene, interrupted by IS2A, 
acetyltransferase homolog; putative 
transferase; nonfunctional; interruped 
by IS2 
insD1 →  coding (440‐444/906 nt)  IS2 transposase TnpB 
ylbE →  pseudogene (114/1259 nt) 
putative protein, C‐ter fragment 
(pseudogene) 
ylbE →  pseudogene (255/1259 nt) 
putative protein, C‐ter fragment 
(pseudogene) 
cusS ←  D435A (GAC→GCC)  
sensory histidine kinase in 
two‐component regulatory system with 
CusR, senses copper ions 
cusS ←  D435A (GAC→GCC)  
sensory histidine kinase in 
two‐component regulatory system with 
CusR, senses copper ions 
insB1–insA     insB1, insA 
insA ← / → uspC  intergenic (‐271/‐264) 
IS1 repressor TnpA/universal stress 
protein 
insB1–insA     insB1, insA 
insA ← / → uspC  intergenic (‐271/‐264) 
IS1 repressor TnpA/universal stress 
protein 
wbbK ←  T87M (ACG→ATG)   lipopolysaccharide biosynthesis protein 
wbbK ←  T87M (ACG→ATG)   lipopolysaccharide biosynthesis protein 
gatC ←  pseudogene (1‐2/442 nt) 
pseudogene, galactitol‐specific enzyme 
IIC component of PTS;transport; 
Transport of small molecules: 
Carbohydrates, organic acids, alcohols; 
PTS system galactitol‐specific enzyme 
IIC 
purL ←  R472S (CGC→AGC)  
phosphoribosylformyl‐glycineamide 
synthetase 
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purL ←  R472S (CGC→AGC)  
phosphoribosylformyl‐glycineamide 
synthetase 
ompR ←  coding (477‐533/720 nt) 
DNA‐binding response regulator in 
two‐component regulatory system with 
EnvZ 
ompR ←  coding (477‐533/720 nt) 
response regulator in two‐component 
regulatory system with EnvZ 
glpR ← / ← glpR  intergenic (‐2/+1) 
pseudogene, DNA‐binding 
transcriptional repressor;regulator; 
Energy metabolism, carbon: Anaerobic 
respiration; repressor of the glp 
operon/pseudogene, DNA‐binding 
transcriptional repressor;regulator; 
Energy metabolism, carbon: Anaerobic 
respiration; repressor of the glp operon 
ppiC ← / ← yifN  intergenic (‐121/+78) 
peptidyl‐prolyl cis‐trans isomerase C 
(rotamase C)/conserved protein 
(pseudogene) 
rhaM ←  Y102S (TAC→TCC)   L‐rhamnose mutarotase 
rpoB →  H526Y (CAC→TAC)   RNA polymerase, beta subunit 
rpoB →  H526Y (CAC→TAC)   RNA polymerase, beta subunit 
rpoC →  K395E (AAA→GAA)   RNA polymerase, beta prime subunit 
rpoC →  K395E (AAA→GAA)   RNA polymerase, beta prime subunit 
gltP → / ← yjcO  intergenic (+587/+55) 
glutamate/aspartate:proton 
symporter/hypothetical protein 
gltP → / ← yjcO  intergenic (+586/+56) 
glutamate/aspartate:proton 
symporter/Sel1 family TPR‐like repeat 
protein 
sgcR ←  coding (735‐738/783 nt) 
putative DNA‐binding transcriptional 
regulator 
bglJ →  S62F (TCT→TTT)   bgl operon transcriptional activator 
nadR → / ← yjjK  intergenic (+102/+206) 
trifunctional protein: nicotinamide 
mononucleotide adenylyltransferase, 
ribosylnicotinamide kinase, 
transcriptional repressor/fused 
predicted transporter subunits of ABC 
superfamily: ATP‐binding components 
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Table 9a. Genomic Variants in E. coli K12 MG1655 (Control and Treatment 
Populations) Generation 200. 
 
Stock  Gene  Pos.  Mutation 
C0, C1, C3, C4, C5, T1, T2, T5  [crl]  257,908  Δ776 bp 
T4  allR → / → gcl  533,893  C→A 
T1, T2, T3, T4, T5  cusS ←  593,467  T→G 
C2, C4, C5, T2, T5  ychE → / → oppA  1,299,499  Δ1,199 bp 
C1, C4, C5, T1, T2, T4, T5  insB1–insA  1,978,503  Δ776 bp 
C1, C2, C3, C4, C5, T1, T2, T4, T5  insA ← / → uspC  1,979,486  IS5 (+) +4 bp 
C0, C1, C2, C3, C4, C5, T1, T2, T3, T4, T5  gatC ←  2,173,361  Δ2 bp 
C2   ccmE ←  2,295,168  C→T 
T1, T2, T4, T5  purL ←  2,694,130  G→T 
C1   rpoA ←  3,440,459  G→A 
T1  ompR ←  3,536,264  Δ1 bp 
T2  ompR ←  3,536,342  Δ12 bp 
T5  ompR ←  3,536,570 
IS3 (–) +4 bp 
:: +TCA 
C0, C1, C2, C3, C4, C5, T1, T2, T3, T4, T5  glpR ← / ← glpR  3,560,455  +G 
T1, T2, T3, T4, T5  rpoB →  4,182,820  C→T 
C2, C3, C4, C5  rpoC →  4,186,532  A→G 
C0, C1, C2, C3, C4, C5, T1, T2, T4, T5  gltP → / ← yjcO  4,296,380  +CG 
 
 
Mutation Description:  = deletion; i = insertion;             = point mutation 
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Table 9b. Genomic Variants (Annotation and Description) Treatment and Control 
Populations, Generation 200 
 
Gene  Annotation  Description
[crl]     [crl] 
allR → / 
→ gcl 
intergenic 
(+67/‐23) 
transcriptional repressor of all and gcl operons; 
glyoxylate‐induced/glyoxylate carboligase 
cusS ← 
D435A 
(GAC→GCC)  
sensory histidine kinase in two‐component regulatory 
system with CusR, senses copper ions 
ychE → / 
→ oppA 
intergenic 
(+254/‐485) 
UPF0056 family inner membrane protein/oligopeptide 
transporter subunit 
insB1–
insA     insB1, insA 
insA ← / 
→ uspC 
intergenic 
(‐271/‐264)  IS1 repressor TnpA/universal stress protein 
gatC ← 
pseudogene 
(1‐2/442 nt) 
pseudogene, galactitol‐specific enzyme IIC component of 
PTS;transport* 
ccmE ← 
V71V 
(GTG→GTA)   periplasmic heme chaperone 
purL ← 
R472S 
(CGC→AGC)   phosphoribosylformyl‐glycineamide synthetase 
rpoA ← 
R191C 
(CGT→TGT)   RNA polymerase, alpha subunit 
ompR ← 
coding 
(321/720 nt) 
response regulator in two‐component regulatory system 
with EnvZ 
ompR ← 
coding 
(232‐243/720 
nt) 
response regulator in two‐component regulatory system 
with EnvZ 
ompR ← 
coding 
(12‐15/720 
nt) 
response regulator in two‐component regulatory system 
with EnvZ 
glpR ← / 
← glpR 
intergenic 
(‐2/+1) 
pseudogene, DNA‐binding transcriptional 
repressor;regulator; Energy metabolism* 
rpoB → 
H526Y 
(CAC→TAC)   RNA polymerase, beta subunit 
rpoC → 
K395E 
(AAA→GAA)   RNA polymerase, beta prime subunit 
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gltP → / 
← yjcO 
intergenic 
(+586/+56) 
glutamate/aspartate:proton symporter/Sel1 family TPR‐like 
repeat protein 
Yellow ‐ Ancestral shared 
Light Blue ‐ Control specific 
Blue ‐‐ Control Adaptation 
Light Orange ‐ Evolved AgNP specific 
Orange ‐ Evolved AgNP shared 
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Figure 1. Population Growth as Measured by Optical Density of the Treatment and 
Control Bacterial Cocktails at Generation 250 Exposed to 40nm Citrate-Coated Silver 
Nanoparticles.    
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Figure 2. Population Growth as Measured by Optical Density of the Treatment and 
Control Bacterial Cocktails at 250 Generations Exposed to 40nm PVP-Coated Silver 
Nanoparticles.  
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Figure 3. Population Growth of Control and Treatment Cocktails as Measured by Optical 
Density of Bacteria Exposed to Different Concentrations of 10 nm Citrate Coated Silver 
Nanoparticles at 250 Generations.  
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Figure 4. Population Growth of Control and Treatment Bacterial Cocktails as Measured 
by Optical Density of Treatment and Control Bacteria at Generation 250 Exposed to 
10nm PVP-Coated Silver Nanoparticles.  
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Figure 5. Population Growth of Control and Treatment Bacterial Cocktails as Measured 
by Optical Density of the Treatment and Control Bacteria at Generation 250 Exposed to 
Bulk Silver Nitrate.  
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Figure 6b. Difference in Colony Forming Units (log 10 FU) for Treatment and Control 
Bacteria at Generation 305 Exposed to Different Concentrations of 10 nm Citrate Coated 
Silver Nanoparticles for 24 Hours. 
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Figure 6a.  Difference in Colony Forming Units (log 10 CFU) for Treatment and 
Control Bacteria at Generation 305 Exposed to Different Concentrations of Bulk Silver 
(AgNO3) over 24 Hours.   
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Figure 6c. Difference in Colony Forming Units (log 10 CFU) for Treatment and Control 
Bacteria at Generation 305 Exposed to Different Concentrations of 40 nm Citrate Coated 
Silver Nanoparticles for 24 Hours. 
 
 
 
 
Figure 6d. Difference in Colony Forming Units (log 10 CFU) for Treatment and Control 
Bacteria at Generation 305 Exposed to Different Concentrations of 10 nm PVP-Coated 
Silver Nanoparticles for 24 Hours. 
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Figure 6e. Difference in Colony Forming Units (log 10 CFU) for Treatment and Control 
Bacteria at Generation 305 Exposed to Different Concentrations of 40 nm PVP-Coated 
Silver Nanoparticles for 24 Hours.  
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Figure 7. SEM Images of E. coli MG1655 (a) No AgNPs were added to this Preparation 
(b) Treated with 20 g/L40 nm PVP-Coated Spherical Silver Nanoparticles.  
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Figure 8. AFM Images of E. coli MG1655 at Generation 250 (a) Control (b) Treatment 
with 250 µg/l 10 nm Citrate-Coated Spherical Silver Nanoparticles.  
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Figure 9. Disc Diffusion Assay to Determine Differences between Control (a) Treatment 
Populations (b) of E. coli K-12 at 250 Generations.  
 
 
 
 
a 
b 
 
 
 
 
 
 
79 
 
 
 
Figure 10. Micro dilution Result of 40nm Citrate Coated to Determine Differences 
between Treated (lines EFGH) and Non-Treated (lines ABCD) 
 
 
 
